Biomarin Pharmaceutical Inc at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript
Good morning, everyone. Thank you for joining us at the Goldman Sachs CEOs Unscripted Conference 2022. We're really pleased to have Jean-Jacques Bienaime, Chairman and CEO of BioMarin, J.J., thank you for joining us this morning.
2022 looks to be an inflection year for BioMarin with the launch of recently approved VOXZOGO and potentially submission and approval for ROCTAVIAN, 2 blockbuster drugs. As you look to this year, where are you focused? And is there anything that you are doing differently that is unique to these 2 products?
Thank you, Salveen. So as you highlighted, indeed, we believe that 2022 will be a transformational year for BioMarin. Our most recently approved product, VOXZOGO, for the treatment of children with achondroplasia is expected to drive us to sustainable GAAP profitability this year. As the only therapeutic treatment available for patients with achondroplasia, this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
